СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ПРОФИЛАКТИКИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ
https://doi.org/10.20996/1819-6446-2012-8-4-561-568
Аннотация
Ингибиторы ренин-ангиотензин-альдостероновой системы, статины, и, возможно, ω-3 полиненасыщенные жирные кислоты могут оказывать влияние на частоту развития фибрилляции предсердий (ФП), т.е. применяться для её профилактики, что в современной литературе обозначается термином «терапия вверх по течению» (upstream treatment). Приведены данные результатов экспериментов и клинических исследований, которые показывают , что применение данных препаратов может быть полезно для первичной профилактики ФП у отдельных категорий пациентов. Тем не менее, достаточных доказательств, чтобы оправдать данные рекомендации и применить их к более широкому кругу пациентов с факторами риска ФП, в настоящее время нет. Таким образом, обосновано продолжение изучения как первичной, так и вторичной профилактики ФП.
Об авторах
Е. А. Протасова
Саратовский научно-исследовательский институт кардиологии
Россия
врач-ординатор
Россия
врач-ординатор
Н. В. Фурман
Саратовский научно-исследовательский институт кардиологии
Россия
Россия
к.м.н., зав. лабораторией неотложной кардиологии
О. В. Решетько
Саратовский государственный медицинский университет им. В.И. Разумовского
Россия
Россия
д.м.н., профессор, зав. кафедрой фармакологии и клинической фармакологии
Список литературы
1. Benjamin E.J., Levy D., Vaziri S.M. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271(11):840–844
2. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001; 285:2370–2375
3. Miyasaka Y ., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County , Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119–25.
4. Heeringa J., van der Kuip D.A., Hofman A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27(8):949–53.
5. Majeed A., Moser K., Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. Heart 2001;86:284–288.
6. Friberg J., Buch P ., Scharling H., et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14:666–72.
7. Nieuwlaat R., Prins M.H., Le Heuzey J.Y ., et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008;29(9):1181–9.
8. van Veldhuisen D.J., Aass H., El Allaf D., et al.; MERIT-HF Study Group. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study . Eur J Heart Fail 2006;8:539–546.
9. Benjamin E.J., Wolf P .A., D’Agostino R.B., et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946–952.
10. Nieuwlaat R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on atrial Fibrillation. Eur Heart J 2005; 26: 2422–2434.
11. Camm A.J., Kirchhof P ., Lip G.Y . et al. Guidelines for the management of atrial fibrillation: the T ask Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360–1420
12. Kozlowski D., Budrejko S., Lip GrY H., et al. Lone atrial fibrillation: what do we know? Heart 2010; 96: 498–503.
13. Le Heuzy J.Y ., Paziaud O., Piot O., et al. Cost of care distribution in atrial fibrillation patients: The CO- CAF study. Am Heart 2004;147:121–6.
14. Stewart S., Murphy N.F ., Walker A., et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90(3):286–92.
15. Reynolds M.R., Essebag V., Zimetbaum P ., et al. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007;18(6):628–33.
16. Ringborg A., Nieuwlaat R., Lindgren P ., et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 2008;10(4):403–11.
17. Heemstra H. E., Nieuwlaat R., Meijboom M., Crijns H. J. The burden of atrial fibrillation in the Netherlands. Neth Heart J 2011;19:373–378.
18. Wolowacz S.E., Samuel M., Brennan V.K., et al. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 2011; 13:1375–85.
19. National guidelines for diagnosis and treatment of atrial fibrillation. Kardiovaskuljarnaja Terapija i Profilaktika 2005; 4(4) suppl 1: 1–36. Russian (Национальные рекомендации по диагностике и лечению фибриляции предсердий. Кардиоваскулярная терапия и профилактика 2005; 4(4) Приложение 1: 1–36).
20. Shilov A.M., Mel'nik M.V., Osija A.O., et al Pathophysiology and principles of treatment of atrial fibrillation. Russkij Medicinskij Zhurnal 2011; 14:877–883. Russian (Шилов А.М., Мельник М.В., Осия А.О., и др. Патофизиология и принципы лечения фибрилляции предсердий. Русский Медицинский Журнал 2011; 14:877–883).
21. Morrow JP ., Reiffel A J., Drug Therapy for Atrial Fibrillation: What Will Its Role Be in the Era of Increasing Use of Catheter Ablation? PACE 2009; 32:108–118.
22. Savelieva I., Kakouros N., Kourliouros A., Camm A. J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011;13:308–328.
23. Savelieva I., Kakouros N., Kourliouros A., Camm A. J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: Secondary prevention. Europace 2011;13:610–625.
24. Savelieva I., Camm A.J. Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation? Am Heart J 2007;154:403–406.
25. Egorov D.F . Prospects for development of non-drug treatments for atrial fibrillation. Vestnik Aritmologii 2007;46: 68–78. Russian (Егоров Д.Ф. Перспективы развития немедикаментозных способов лечения фибрилляции предсердий. Вестник аритмологии 2007;46: 68–78).
26. Marcus G.M., Smith L.M., Vittinghoff E. et al. A fi rstdegree family history in lone atrial fibrillation patients Heart Rhythm 2008; 5: 826–830.
27. Schotten U., Verheule S., Kirchhof P ., Goette A. Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal. Physiol Rev 2011; 91: 265–325.
28. Hobbs W.J., Van Gelder I.C., Fitzpatrick A.P ., et al. The role of atrial electrical remodeling in the progression of focal atrial ectopy to persistent atrial fibrillation. J Cardiovasc Electrophysiol 1999;10: 866–70.
29. Morillo C.A., Klein G.J., Jones D.L., et al. Chronic rapid atrial pacing: structural, functional and elec- trophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995;91: 1588–95.
30. Brundel B.J., Henning R.H., Kampinga H.H. et al. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 2002;54:315–324.
31. Ravens U., Cerbai E. Role of potassium currents in cardiac arrhythmias. Europace 2008; 10(10): 1133–7.
32. Wang Z., Feng J., Nattel S. Idiopathic atrial fibrillation in dogs: electrophysiologic determinants and mechanism of antiarrhythmic action of flecainide. J Am Coll Cardiol 1995; 26:277–286.
33. Hoit B.D., Shao Y ., Gabel M. Et al. Left atrial mechanical and biomechanical adaptation to pacing induced heart failure. Cardivasc Res 1995; 29: 469–474.
34. Kumagai K., Nakashima H., Urata H. et al. Effects of angiotensin II type I receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197–2204.
35. Kistler P .M., Sanders P ., Dodic M. Et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: imlications for development of atrial fibrillation. Eur Heart J 2006;27:3045–56.
36. Thijssen V., Ausma J., Lin G. et al. Structural changes of atrial myocardium during chronic atrial fibrillation ardiovasc. Path 2000;9:17–28.
37. Issac TT., Dokainish H, Lakkis N M., Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation A Systematic Review of the Published Data. J Am Coll Cardiol 2007;50:2021–28.
38. Schnabel R.B., Sullivan L.M., Levy D. et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009; 373: 739–45.
39. Williams B. Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol 2001;87(8A):10–17.
40. Kourliouros A., Savelieva I., Kiotsekoglou A., et al. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 2009;157:243–52.
41. Nasonov EL, Paniukova EV, Aleksandrova EN. C-reactive protein--marker of inflammation in atherosclerosis (new data). Kardiologiia 2002;42(7):53–62. Russian (Насонов Е.Л., Панюкова Е.В., Александрова Е.Н. С-реактивный белок — маркер воспаления при атеросклерозе (новые данные). Кардиология 2002; 7: 53—62).
42. Goette A., Staakc Th., Rocken Ch. Increased expression of extracellular signal_regulated kinase and angiotensin_con_verting enzyme in human atrial during atrial fibrillation. J Am Coll Cardiol 2000; 35:1669—77.
43. Cardin S., Li D., Thorin-Trescases N., et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res 2003; 60: 315–25.
44. Pedersen O.D., Bagger H., Kober L., Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376–80.
45. Vermes E., Tardif J.C., Bourassa M.G. et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107:2926–31.
46. Maggioni A.P ., Latini R., Carson P .E. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548–57.
47. Ducharme A., Swedberg K., Pfeffer M.A. et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152:86–92.
48. Healey J.S., Baranchuk A., Crystal E. et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832–9.
Рецензия
Для цитирования:
Протасова Е.А., Фурман Н.В., Решетько О.В. СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ПРОФИЛАКТИКИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ. Рациональная Фармакотерапия в Кардиологии. 2012;8(4):561-568. https://doi.org/10.20996/1819-6446-2012-8-4-561-568
For citation:
Protasova E.A., Furman N.V., Reshet'ko O.V. UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION. Rational Pharmacotherapy in Cardiology. 2012;8(4):561-568. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-4-561-568
Просмотров:
668
Послать статью по эл. почте 